Merck Sharp and Dohme reports positive new Keytruda study data

Merck Sharp and Dohme has announced new clinical data that demonstrates the wide range of benefits offered by its anti-PD-1 cancer therapy Keytruda.

During this year's European Society for Medical Oncology (ESMO) Congress, the company reported the finding of several new trials, showing the effectiveness of the treatment across a wide range of indications.

Results from the KEYNOTE-002 trial showed that the drug provided overall and progression-free survival benefits compared to chemotherapy in patients with ipilimumab-refractory advanced melanoma, while data from KEYNOTE-010 showed similar benefits in patients with previously-treated metastatic non-small cell lung cancer (NSCLC).

KEYNOTE-021 and KEYNOTE-024 further demonstrated the efficacy of the therapy in NSCLC in combination with chemotherapy and as a monotherapy, respectively, with KEYNOTE-052 offering additional evidence of the advantages it could provide for patients with unresectable or metastatic urothelial cancer.

Dr Roger Dansey, senior vice-president for oncology late-stage development at Merck Research Laboratories, said: "We have a growing body of evidence of Keytruda's activity in a range of cancers and treatment settings."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.